

ASX Announcement

7 July 2026

ReNerve Secures Marketing Approval for NervAlign® Nerve Cuff in Indonesia

Key Highlights

- ReNerve Limited (ASX: RNV) has received marketing approval (registration) for its **NervAlign® Nerve Cuff** in Indonesia.
- Indonesia joins ReNerve's growing Asia-Pacific footprint alongside the United States, New Zealand, Hong Kong, Thailand and Malaysia.
- As the world's fourth most populous nation — with over 280 million people — Indonesia represents one of the largest single-country opportunities in ReNerve's regional strategy.
- The Asia-Pacific nerve repair market is estimated to be worth around USD \$100 million in 2026¹, with Indonesia's scale and high burden of trauma-related nerve injury making it a strategically significant market.

ReNerve Limited (ASX, "ReNerve" or "the Company"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("PNI") repair, is pleased to announce that it has received marketing approval for its NervAlign® Nerve Cuff in Indonesia.

The approval opens access to Southeast Asia's largest economy and one of the region's most significant addressable markets for nerve repair. Indonesia's demographic and clinical profile points to substantial and growing demand for peripheral nerve repair solutions:

Population scale. Indonesia is the world's fourth most populous country, with a population of over 280 million.

Trauma burden. Road trauma is a leading source of peripheral nerve injury. The World Health Organisation (WHO) estimated more than 30,000 road-traffic deaths in Indonesia, with far larger numbers of serious injuries due to reduced road speeds and motorcycles, the dominant mode of transport accounting for the majority of crashes and severe limb injuries. Road crashes were estimated to cost Indonesia around USD \$38 billion in 2021, roughly 3% of GDP.²

"Securing approval in Indonesia is a significant milestone in our Asia-Pacific expansion strategy. Indonesia is one of the largest and fastest-growing healthcare markets in the region, and the clinical need for effective peripheral nerve repair — driven by both trauma and diabetes — is substantial,"

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

² <https://www.worldlifeexpectancy.com/indonesia-road-traffic-accidents>

<https://asiantransportobservatory.org/analytical-outputs/roadsafetyprofiles/indonesia-road-safety-profile-2025/>



“This approval is further validation of the strength of our clinical data and the clear benefit the NervAlign® Nerve Cuff delivers to patients and surgeons. We look forward to working with our partners to bring the product to Indonesian clinicians and patients,” said Dr Julian Chick, CEO of ReNerve.

- ENDS -

This announcement has been approved for release by the Company’s Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)


ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve’s first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

For personal use only

Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

On market

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.

In development

- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.6 billion in 2024 and is projected to reach \$6.2 billion by 2031.³

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

For personal use only

³ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)